• PharmaCielo revenue rose to $1.4 million for Q1 2026, up from $0.3 million a year earlier.
• Net loss widened to $1.44 million; loss per share was $0.007.
• Gross profit swung to $0.52 million from a $61,000 loss.
• Adjusted EBITDA loss (non-IFRS) widened to $689,000, reflecting a one-time non-recurring expense.
• Results reflected a broader geographic footprint and new dried flower sales to Europe; management expects positive operating cash flow going forward.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmacielo Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608280745NEWSFILECNPR____20260828_311888_1) on August 28, 2026, and is solely responsible for the information contained therein.